Jenna Ablott
YOU?
Author Swipe
View article: <scp>NT</scp> ‐ <scp>proBNP</scp> and <scp>BNP</scp> Testing in Pulmonary Arterial Hypertension: Point‐of‐Care and Remote Monitoring
<span>NT</span> ‐ <span>proBNP</span> and <span>BNP</span> Testing in Pulmonary Arterial Hypertension: Point‐of‐Care and Remote Monitoring Open
Background and Objectives Brain natriuretic peptide (BNP) and N‐terminal prohormone of BNP (NT‐proBNP) are important biomarkers in pulmonary arterial hypertension (PAH). However, results are rarely available at the time of clinical assessm…
View article: Comparability, acceptability and longitudinal adherence with digital emPHasis-10 in pulmonary arterial hypertension
Comparability, acceptability and longitudinal adherence with digital emPHasis-10 in pulmonary arterial hypertension Open
Digital emPHasis-10 is an app-based patient-reported outcome measure for trial or clinical use by patients with pulmonary hypertension. This letter demonstrates this novel tool's validity, longer-term adherence and high acceptability score…
View article: 158 Seasonal variation in remote actigraphy in patients with pulmonary arterial hypertension
158 Seasonal variation in remote actigraphy in patients with pulmonary arterial hypertension Open
Introduction Remote assessment of real-world physical activity is a potentially important addition in evaluating the effect of therapies on how a patient "feels, functions and survives". Actigraphy, the most used measure of physical activi…
View article: Pulmonary Hypertension: Intensification and Personalization of Combination Rx (PHoenix): A phase IV randomized trial for the evaluation of dose‐response and clinical efficacy of riociguat and selexipag using implanted technologies
Pulmonary Hypertension: Intensification and Personalization of Combination Rx (PHoenix): A phase IV randomized trial for the evaluation of dose‐response and clinical efficacy of riociguat and selexipag using implanted technologies Open
Approved therapies for the treatment of patients with pulmonary arterial hypertension (PAH) mediate pulmonary vascular vasodilatation by targeting distinct biological pathways. International guidelines recommend that patients with an inade…
View article: Pulmonary Hypertension: Intensification and Personalisation of Combination Rx (PHoenix): A phase IV randomised trial for the evaluation of dose-response and clinical efficacy of riociguat and selexipag using implanted technologies
Pulmonary Hypertension: Intensification and Personalisation of Combination Rx (PHoenix): A phase IV randomised trial for the evaluation of dose-response and clinical efficacy of riociguat and selexipag using implanted technologies Open
Approved therapies for pulmonary arterial hypertension (PAH) mediate pulmonary vascular vasodilatation by targeting distinct biological pathways. Patients identified as intermediate-low risk, according to a four-strata risk assessment mode…
View article: 153 Differences in physical activity, heart rate and heart variability during clinical worsening events in patients with pulmonary arterial hypertension (pah)
153 Differences in physical activity, heart rate and heart variability during clinical worsening events in patients with pulmonary arterial hypertension (pah) Open
Introduction Hospital-based evaluation of exercise capacity and invasively measured haemodynamics are used for risk-stratification and determination of therapeutic efficacy in patients with pulmonary arterial hypertension (PAH). Minimally-…
View article: 138 Physiological detection of clinical worsening and therapeutic response using implanted remote technologies in pah
138 Physiological detection of clinical worsening and therapeutic response using implanted remote technologies in pah Open
Introduction European guidelines for pulmonary hypertension (PH) recommend comprehensive risk stratification to optimise therapy and achieve/maintain a low risk profile (table 1) using repeated hospital-based investigations undertaken in s…
View article: 137 Design and validation of a physiological risk score for pulmonary arterial hypertension (pah)
137 Design and validation of a physiological risk score for pulmonary arterial hypertension (pah) Open
Introduction European guidelines for pulmonary hypertension (PH) recommend comprehensive risk stratification to optimise therapy and achieve/maintain a low risk profile1,3 using repeated hospital-based investigations undertaken in speciali…
View article: 154 Stability of daily physical activity as a remote measure of clinical risk in pulmonary arterial hypertension (pah)
154 Stability of daily physical activity as a remote measure of clinical risk in pulmonary arterial hypertension (pah) Open
Introduction European guidelines for diagnosis and treatment of pulmonary hypertension recommend the use of risk stratification to optimise therapy and achieve/maintain a low risk profile.1 The COMPERA 2.0 four strata model is used to eval…
View article: 196 The relationship of physical activity, heart rate variability, and night heart rate to established measures of clinical risk in patients with pulmonary arterial hypertension (pah)
196 The relationship of physical activity, heart rate variability, and night heart rate to established measures of clinical risk in patients with pulmonary arterial hypertension (pah) Open
Introduction Exercise capacity is used for risk stratification in patients with pulmonary arterial hypertension (PAH) and for the evaluation of clinical efficacy in clinical studies, however, this requires a hospital-based assessment. Phys…
View article: Remote monitored physiological response to therapeutic escalation and clinical worsening in patients with pulmonary arterial hypertension
Remote monitored physiological response to therapeutic escalation and clinical worsening in patients with pulmonary arterial hypertension Open
Background International guidelines recommend regular, hospital-based risk stratification to aid assessment and management of patients with pulmonary arterial hypertension. Technological advances enable daily, remote measurement of cardiop…